• Johnson and Johnson ($JNJ) has agreed to buy Actelion for $30 billion. The company will acquire all of the outstanding shares of Actelion for $280 per share, representing a 23 percent premium to Actelion's closing price on Wednesday of 227.4 Swiss francs. The consideration is payable in U.S. dollars. This all-cash deal has been unanimously approved by the boards of directors of both companies.
The deal will helps boost Johnson & Johnson's drug pipeline and diversify its prospects. Actelion was also courted by Sanofi, however, the talks fell through. Johnson & Johnson said it expected the transaction to be immediately accretive to its adjusted earnings per share and accelerate its revenue and earnings growth rates. The transaction will be funded with cash held by the company outside the United States. Actelion will spin out its research and development unit into a standalone company, under the name of R&D NewCo.
• CareDx (CDNA) announced the acquisition of Conexio SBT Resolver products and Assign SBT analysis software for high resolution HLA typing from Illumina. HLA (human leukocyte antigen) typing is used to match a bone marrow or cord blood donor with the recipient. The companies did not disclose the financial terms and conditions.